Светлана Проценко

1.2k total citations · 1 hit paper
63 papers, 737 citations indexed

About

Светлана Проценко is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Светлана Проценко has authored 63 papers receiving a total of 737 indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Oncology, 17 papers in Molecular Biology and 15 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Светлана Проценко's work include Cancer Immunotherapy and Biomarkers (24 papers), CAR-T cell therapy research (16 papers) and Immunotherapy and Immune Responses (13 papers). Светлана Проценко is often cited by papers focused on Cancer Immunotherapy and Biomarkers (24 papers), CAR-T cell therapy research (16 papers) and Immunotherapy and Immune Responses (13 papers). Светлана Проценко collaborates with scholars based in Russia, United States and Poland. Светлана Проценко's co-authors include Lev Demidov, Thomas Eigentler, Karl D. Lewis, Caroline Robert, Rodrigo Perez Pereira, Ralf Gutzmer, Grant A. McArthur, Piotr Rutkowski, Paolo A. Ascierto and Helen Gogas and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Светлана Проценко

42 papers receiving 700 citations

Hit Papers

Atezolizumab, vemurafenib, and cobimetinib as first-line ... 2020 2026 2022 2024 2020 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial
    2020 442 citations Ralf Gutzmer, Daniil Stroyakovskiy et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Светлана Проценко Russia 8 621 298 176 118 59 63 737
Samantha Bowyer Australia 16 489 0.8× 220 0.7× 170 1.0× 92 0.8× 81 1.4× 47 652
Brian Belmontes United States 13 421 0.7× 322 1.1× 169 1.0× 203 1.7× 84 1.4× 22 757
Marye J. Boers‐Sonderen Netherlands 14 346 0.6× 194 0.7× 92 0.5× 114 1.0× 43 0.7× 43 523
V. Guillem Porta Spain 9 474 0.8× 251 0.8× 91 0.5× 116 1.0× 196 3.3× 16 647
Rodrigo Perez Pereira Brazil 6 467 0.8× 296 1.0× 155 0.9× 90 0.8× 40 0.7× 11 583
François‐Xavier Danlos France 12 400 0.6× 177 0.6× 212 1.2× 144 1.2× 54 0.9× 36 644
Jacek Mackiewicz Poland 13 339 0.5× 297 1.0× 129 0.7× 49 0.4× 148 2.5× 55 563
Mariana Brandão Belgium 16 468 0.8× 154 0.5× 76 0.4× 200 1.7× 181 3.1× 65 721
Bryan A. Faller United States 11 325 0.5× 196 0.7× 47 0.3× 179 1.5× 83 1.4× 32 532
Djura Piersma Netherlands 15 338 0.5× 200 0.7× 97 0.6× 51 0.4× 30 0.5× 50 649

Countries citing papers authored by Светлана Проценко

Since Specialization
Citations

This map shows the geographic impact of Светлана Проценко's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Светлана Проценко with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Светлана Проценко more than expected).

Fields of papers citing papers by Светлана Проценко

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Светлана Проценко. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Светлана Проценко. The network helps show where Светлана Проценко may publish in the future.

Co-authorship network of co-authors of Светлана Проценко

This figure shows the co-authorship network connecting the top 25 collaborators of Светлана Проценко. A scholar is included among the top collaborators of Светлана Проценко based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Светлана Проценко. Светлана Проценко is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Проценко, Светлана, et al.. (2023). Immune checkpoint inhibitors for the treatment of solid tumors in HIV-infected patients: is it worth the risk?. SHILAP Revista de lepidopterología. 22(1). 141–150. 1 indexed citations
2.
Проценко, Светлана, et al.. (2023). Неврологические осложнения противоопухолевой лекарственной терапии. Malignant tumours. 13(3s2-2). 302–311.
3.
Проценко, Светлана, et al.. (2022). Real-world data on the incidence of immune-related adverse events associated with anti-PD-1/PD-L1 treatment in Russia. Voprosy Onkologii. 68(2). 188–199. 2 indexed citations
4.
5.
Vf, Semiglazov, Светлана Проценко, В. В. Семиглазов, et al.. (2021). Immunology and immunotherapy in the complex treatment of malignant tumors. SHILAP Revista de lepidopterología. 248–257. 3 indexed citations
6.
Проценко, Светлана, et al.. (2021). Experience of using prolgolimab in real clinical practice. Фарматека. 7_2021. 51–55.
7.
Проценко, Светлана, et al.. (2020). Modern combined targeted and immunotherapy of metastatic skin melanoma. Meditsinskiy sovet = Medical Council.
8.
Tsimafeyeu, Ilya, et al.. (2020). Nivolumab in patients with metastatic renal cell carcinoma and chronic hepatitis C virus infection. Cancer Immunology Immunotherapy. 69(6). 983–988. 10 indexed citations
9.
10.
Ulrikh, Е. A., et al.. (2020). Successful treatment of high-risk gestational trophoblastic disease in a patient with intolerance to standard chemotherapy (clinical case). SHILAP Revista de lepidopterología. 16(3). 67–71. 1 indexed citations
11.
Semiglazova, Т. Yu., et al.. (2019). The predictive value of nutritional deficiency in the treatment of patients with locally advanced stomach cancer. Фарматека. 12_2019. 9–14. 1 indexed citations
12.
Semiglazova, Т. Yu., et al.. (2018). Efferent therapy in the first-line drug treatment of metastatic colorectal cancer. Meditsinskiy sovet = Medical Council. 172–175. 2 indexed citations
13.
14.
Лактионов, К. К., Alla Arzumanyan, Л. В. Болотина, et al.. (2018). Efficacy of nivolumab (Nivo) as 2+ line treatment and quality of life (QoL) in advanced refractory non-small cell lung cancer (NSCLC) patients: Interim results of observational prospective study.. Journal of Clinical Oncology. 36(15_suppl). e21126–e21126. 1 indexed citations
15.
Носов, А. К., et al.. (2017). Melanoma of the penis and urethra: literature review and observations from clinical practice. Cancer Urology. 13(2). 113–120. 1 indexed citations
16.
Semiglazova, Т. Yu., et al.. (2016). TARGETED THERAPY OF NSCLC WITH EGFR ACTIVATING MUTATIONS IMPROVES THE QUALITY OF LIFE OF PATIENTS. Meditsinskiy sovet = Medical Council. 56–65. 1 indexed citations
17.
Проценко, Светлана, et al.. (2015). [Gefitinib therapy in advanced non-small cell lung cancer in patients with EGFR mutations: cost-effectiveness analysis].. PubMed. 61(4). 676–80. 1 indexed citations
18.
Проценко, Светлана, et al.. (2015). BRAF-mutated clear cell sarcoma is sensitive to vemurafenib treatment. Investigational New Drugs. 33(5). 1136–1143. 16 indexed citations
19.
Проценко, Светлана, et al.. (2014). Modern options in personalized therapy of metastatic cutaneous melanoma. SHILAP Revista de lepidopterología. 1 indexed citations
20.
Moiseyenko, Vladimir, et al.. (2010). Phase II study of metronomic chemotherapy (MC) with irinotecan (CPT-11) in patients with refractory metastatic colorectal cancer (MCRC).. Journal of Clinical Oncology. 28(15_suppl). e14109–e14109. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Samantha Bowyer Breakdown of academic impact, for papers by Brian Belmontes Breakdown of academic impact, for papers by Marye J. Boers‐Sonderen Breakdown of academic impact, for papers by V. Guillem Porta Breakdown of academic impact, for papers by Rodrigo Perez Pereira Breakdown of academic impact, for papers by François‐Xavier Danlos Breakdown of academic impact, for papers by Jacek Mackiewicz Breakdown of academic impact, for papers by Mariana Brandão Breakdown of academic impact, for papers by Bryan A. Faller Breakdown of academic impact, for papers by Djura Piersma
Rankless by CCL
2026